Company intelligence / Profile preview

Epizyme, Inc.

Cambridge, Massachusetts, United Statesorpha.net ↗

Ownership: Private
Employees: ~500
Development stage: Commercial

Overview

Epizyme's lead medicine Tazverik (tazemetostat) received FDA Accelerated Approval in 2020 for relapsed or refractory follicular lymphoma and epithelioid sarcoma. The company also has EZM0414, a SETD2 inhibitor with FDA Fast Track status in Phase I/Ib trials for multiple myeloma and diffuse large B-cell lymphoma[1][4].

Therapeutic areas: OncologyHematology
Modalities: Small moleculesepigenetic therapies
Industry: Biotech

Drug pipeline

3 assets

tazemetostat

Commercial

Indications: Follicular lymphoma, Epithelioid sarcoma

2 more assets in the full pipeline.

Request access →

Partnerships

GSK (terminated)Genentech (clinical trial combinations)

Beyond the preview

Go deeper on Epizyme, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epizyme, Inc..

Explore the full profile